Abstract
Correction for ‘Chiral ruthenium polypyridyl complexes as mitochondria-targeted apoptosis inducers’ by Tianfeng Chen et al., Med. Chem. Commun., 2010, 1, 73–75.
The authors regret that in Table 1 of their manuscript the data for Δ-3 and Λ-3 were swapped. The corrected table is shown below.
Table 1. Cytotoxic effects of chiral Ru polypyridyl complexes on human cancer and normal cell lines.
| IC50/μM | ||||||
| Complexes | A375 | HepG2 | SW620 | PC-3 | HS68 | HK-2 |
| Δ-1 | 35.3 ± 4.2 | 19.9 ± 2.5 | 45.2 ± 3.3 | 99.1 ± 7.2 | — | — |
| Λ-1 | 28.1 ± 3.7 | 11.4 ± 1.3 | 29.9 ± 2.0 | 82.7 ± 5.6 | — | — |
| Δ-2 | 48.4 ± 6.3 | 16.6 ± 2.3 | 36.6 ± 4.5 | >200 | — | — |
| Λ-2 | 49.9 ± 8.5 | 19.9 ± 1.7 | 51.0 ± 3.4 | >200 | — | — |
| Δ-3 | 17.7 ± 2.6 | 54.8 ± 6.4 | 33.2 ± 2.2 | >200 | — | — |
| Λ-3 | 5.9 ± 1.1 | 10.0 ± 1.2 | 18.9 ± 0.9 | 79.5 ± 8.1 | 18.8 ± 3.9 | 108.5 ± 9.3 |
| Cisplatin | 7.3 ± 0.8 | 13.6 ± 2.0 | 30.0 ± 4.1 | 36.2 ± 2.9 | 1.8 ± 0.7 | 10.3 ± 2.1 |
In addition, on page 74, left column, top paragraph, the IC50 values for cisplatin against HS68 and HK-2 cells should be corrected to show ‘cisplatin (1.8 and 10.3 μM respectively)’ instead of ‘cisplatin (4.8 and 3.2 μM respectively)’.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.